RECURSION PHARMACEUTICALS IN's ticker is RXRX and the CUSIP is 75629V104. A total of 158 filers reported holding RECURSION PHARMACEUTICALS IN in Q1 2023. The put-call ratio across all filers is 0.85 and the average weighting 0.9%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $839,962 | +0.1% | 109,799 | -2.2% | 0.00% | +50.0% |
Q2 2023 | $838,761 | +149.9% | 112,284 | +123.2% | 0.00% | +100.0% |
Q1 2023 | $335,574 | -5.8% | 50,311 | +8.9% | 0.00% | 0.0% |
Q4 2022 | $356,056 | -53.9% | 46,181 | -36.3% | 0.00% | -50.0% |
Q3 2022 | $772,000 | +112.7% | 72,523 | +62.4% | 0.00% | +100.0% |
Q2 2022 | $363,000 | -66.7% | 44,644 | -70.7% | 0.00% | -50.0% |
Q1 2022 | $1,090,000 | -58.2% | 152,300 | 0.0% | 0.00% | -60.0% |
Q4 2021 | $2,609,000 | +315.4% | 152,300 | +457.9% | 0.01% | +400.0% |
Q3 2021 | $628,000 | -36.9% | 27,300 | 0.0% | 0.00% | -50.0% |
Q2 2021 | $996,000 | – | 27,300 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Obvious Management Services, L.L.C. | 3,985,087 | $42,401,000 | 100.00% |
Two Sigma Ventures, LP | 903,400 | $9,612,000 | 100.00% |
DCVC Opportunity Fund II GP, LLC | 3,951,141 | $42,040,000 | 54.37% |
Data Collective IV GP, LLC | 5,941,120 | $63,214,000 | 49.97% |
MIC Capital Management UK LLP | 8,451,758 | $89,927,000 | 16.21% |
MV Management XI, L.L.C. | 1,971,908 | $20,981,000 | 15.20% |
ArchPoint Investors | 1,116,126 | $11,876,000 | 4.85% |
HARVARD MANAGEMENT CO INC | 1,509,254 | $16,058,000 | 2.00% |
PLATINUM INVESTMENT MANAGEMENT LTD | 2,251,971 | $23,961,000 | 1.00% |
Duquesne Family Office | 1,385,950 | $14,747,000 | 0.84% |